When a CDK4/6 inhibitor was used in combination with another drug therapy (fulvestrant, letrozole, anastrozole, or exemestane) the odds of serious cases of leukopenia decreased (OR = 0.294, 95% CI: 0.14–0.62). This evidence concerns the gene CDK4 and Decreased total leukocyte count.